Tango Therapeutics, Inc.
TNGX
Rank in Stocks
#4546
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Share Price
$27.18
Last synced: 2026-07-31
Market Cap
$3.38B
Change (1 day)
-1.41%
Change (1 year)
197.05%
Country
US
Trade Tango Therapeutics, Inc. (TNGX)
Category
Healthcare
Earnings for Tango Therapeutics, Inc. (TNGX)
Earnings in Jun 2026 TTM: $-123.78M
According to Tango Therapeutics, Inc. latest financial reports the company's current earnings are $-123.78M. In 2023 the company made an earning of $-101.61M, an increase over its 2022 earnings that were of $-108.12M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Tango Therapeutics, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
